Phase II trial of daily oral perillyl alcohol (NSC 641066) in treatment-refractory metastatic breast cancer

By Bailey Howard   Attia Steven   Love Richard   Fass Terri   Chappell Rick   Tutsch Kendra   Harris Linda   Jumonville Alcee   Hansen Richard   Shapiro Gary   Stewart James  

Cancer Chemotherapy and Pharmacology, Vol. 62, Iss. 1, 2008-06 ,pp. : 149-157

Springer Publishing Company

Access to resources Recommend Favorite

A Phase II Trial of Daily Perillyl Alcohol in Patients with Advanced Ovarian Cancer: Eastern Cooperative Oncology Group Study E2E96

By Bailey H.H.   Levy D.   Harris L.S.   Schink J.C.   Foss F.   Beatty P.   Wadler S.  

Gynecologic Oncology, Vol. 85, Iss. 3, 2002-06 ,pp. : 464-468

Academic Press

Access to resources Recommend Favorite

Figitumumab in patients with refractory metastatic colorectal cancer previously treated with standard therapies: a nonrandomized, open-label, phase II trial

By Becerra Carlos   Salazar Ramon   Garcia-Carbonero Rocio   Thomas Anne   Vázquez-Mazón Federico   Cassidy James   Maughan Tim   Castillo Manuel   Iveson Tim   Yin Donghua   Green Stephanie   Bergsland Emily  

Cancer Chemotherapy and Pharmacology, Vol. 73, Iss. 4, 2014-04 ,pp. : 695-702

Springer Publishing Company

Access to resources Recommend Favorite

Phase II Trial Alternating FOLFOX-6 and FOLFIRI Regimens in Second-Line Therapy of Patients with Metastatic Colorectal Cancer (FIREFOX Study)

By Hebbar Mohamed   Tournigand Christophe   Lledo Gérard   Mabro May   André Thierry   Louvet Christophe   Aparicio Thomas   Flesch Michel   Varette Charles   de Gramont Aimery   Group (GERCOR) Oncology  

Cancer Investigation, Vol. 24, Iss. 2, 2006-05 ,pp. : 154-159

Informa Healthcare

Access to resources Recommend Favorite

A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer

By Modi Shanu  

Breast Cancer Research and Treatment, Vol. 90, Iss. 2, 2005-03 ,pp. : 157-163

Springer Publishing Company

Access to resources Recommend Favorite